272 related articles for article (PubMed ID: 32163528)
1. Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease.
Paton DM
Drugs Today (Barc); 2020 Feb; 56(2):125-134. PubMed ID: 32163528
[TBL] [Abstract][Full Text] [Related]
2. The belated US FDA approval of the adenosine A
Chen JF; Cunha RA
Purinergic Signal; 2020 Jun; 16(2):167-174. PubMed ID: 32236790
[TBL] [Abstract][Full Text] [Related]
3. The role of istradefylline in the Parkinson's disease armamentarium.
Müller T
Expert Opin Pharmacother; 2023 May; 24(7):863-871. PubMed ID: 37029952
[TBL] [Abstract][Full Text] [Related]
4. Occupancy of adenosine A
Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
[TBL] [Abstract][Full Text] [Related]
5. Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.
Perez-Lloret S; Merello M
Expert Opin Pharmacother; 2014 Jun; 15(8):1097-107. PubMed ID: 24673462
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study.
Hatano T; Kano O; Sengoku R; Yoritaka A; Suzuki K; Nishikawa N; Mukai Y; Nomura K; Yoshida N; Seki M; Matsukawa MK; Terashi H; Kimura K; Tashiro J; Hirano S; Murakami H; Joki H; Uchiyama T; Shimura H; Ogaki K; Fukae J; Tsuboi Y; Takahashi K; Yamamoto T; Yanagisawa N; Nagayama H
BMC Neurol; 2022 Mar; 22(1):71. PubMed ID: 35241003
[TBL] [Abstract][Full Text] [Related]
7. Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.
Zhu C; Wang G; Li J; Chen L; Wang C; Wang Y; Lin P; Ran H
Neurol Res; 2014 Nov; 36(11):1028-34. PubMed ID: 24725292
[TBL] [Abstract][Full Text] [Related]
8. Istradefylline - a first generation adenosine A
Jenner P; Mori A; Aradi SD; Hauser RA
Expert Rev Neurother; 2021 Mar; 21(3):317-333. PubMed ID: 33507105
[No Abstract] [Full Text] [Related]
9. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.
Jenner P
Expert Opin Investig Drugs; 2005 Jun; 14(6):729-38. PubMed ID: 16004599
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.
Tao Y; Liang G
Cell Biochem Biophys; 2015 Jan; 71(1):57-62. PubMed ID: 25096504
[TBL] [Abstract][Full Text] [Related]
11. Influence of istradefylline on non-motor symptoms of Parkinson's disease: A subanalysis of a 1-year observational study in Japan (J-FIRST).
Shimo Y; Maeda T; Chiu SW; Yamaguchi T; Kashihara K; Tsuboi Y; Nomoto M; Hattori N; Watanabe H; Saiki H;
Parkinsonism Relat Disord; 2021 Oct; 91():115-120. PubMed ID: 34583302
[TBL] [Abstract][Full Text] [Related]
12. Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis.
Chen W; Wang H; Wei H; Gu S; Wei H
J Neurol Sci; 2013 Jan; 324(1-2):21-8. PubMed ID: 23085003
[TBL] [Abstract][Full Text] [Related]
13. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
[TBL] [Abstract][Full Text] [Related]
14. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
[TBL] [Abstract][Full Text] [Related]
15. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.
Mizuno Y; Kondo T;
Mov Disord; 2013 Jul; 28(8):1138-41. PubMed ID: 23483627
[TBL] [Abstract][Full Text] [Related]
16. An overview of adenosine A2A receptor antagonists in Parkinson's disease.
Jenner P
Int Rev Neurobiol; 2014; 119():71-86. PubMed ID: 25175961
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials.
Hauser RA; Hattori N; Fernandez H; Isaacson SH; Mochizuki H; Rascol O; Stocchi F; Li J; Mori A; Nakajima Y; Ristuccia R; LeWitt P
J Parkinsons Dis; 2021; 11(4):1663-1675. PubMed ID: 34486986
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of istradefylline in patients with Parkinson's disease: interim analysis of a post-marketing surveillance study in Japan.
Takahashi M; Fujita M; Asai N; Saki M; Mori A
Expert Opin Pharmacother; 2018 Oct; 19(15):1635-1642. PubMed ID: 30281377
[TBL] [Abstract][Full Text] [Related]
19. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience.
Hauser RA; Schwarzschild MA
Drugs Aging; 2005; 22(6):471-82. PubMed ID: 15974638
[TBL] [Abstract][Full Text] [Related]
20. The effect of istradefylline for Parkinson's disease: A meta-analysis.
Sako W; Murakami N; Motohama K; Izumi Y; Kaji R
Sci Rep; 2017 Dec; 7(1):18018. PubMed ID: 29269791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
